ArticleAnnals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia2019
PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.
Article in Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Trial
- Clinicopathological-CT model for predicting PD-L1 expression in resectable early-stage non-small cell lung cancer.Journal of thoracic disease · 2025Article
- High PD-L1 expression correlates with lymph node metastasis in patients who have undergone radical surgery for primary pulmonary adenocarcinoma.Journal of thoracic disease · 2025Article
- The Role of Surgery for Stage 0 Adenocarcinoma In Situ of the Lung: A National Analysis.Journal of clinical medicine · 2025Article
- Impact of KRAS mutation subtypes on morphological heterogeneity and immune landscape in surgically treated lung adenocarcinoma.Translational lung cancer research · 2025Article
- Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASAnnals of oncology : official journal of the European Society for Medical Oncology · 2025Article
- Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer.Non-coding RNA research · 2025Review
- [Advances on Molecular Mechanism and Clinical Treatment in Invasive Mucinous Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Establishment and verification of novel TNM staging system for lung mucinous adenocarcinoma.BMC cancer · 2024Article
- Nonlinear association between PD-L1 expression levels and the risk of postoperative recurrence in non-small cell lung cancer.Scientific reports · 2024Article
- Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.Cancer science · 2024Article
- Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma).Therapeutic advances in medical oncology · 2024Article
- Impact of lung adenocarcinoma subtypes on survival and timing of brain metastases.Frontiers in oncology · 2024Article
- Prognostic factors of resected pathological stage I lung adenocarcinoma: evaluating subtypes and PD-L1/CD155 expression.Scientific reports · 2023Article
- ASO Author Reflections: Expression Changes in Programmed Death Ligand 1 in Subcentimeter Lung Adenocarcinoma.Annals of surgical oncology · 2023Article
- Lung adenocarcinoma with micropapillary and solid patterns: Recurrence rate and trends.Thoracic cancer · 2023Article
- Cullin7 induces docetaxel resistance by regulating the protein level of the antiapoptotic protein Survivin in lung adenocarcinoma cells.Journal of thoracic disease · 2023Article
- Relationship between PD-L1 expression and molecular aberrances in lung adenocarcinoma with solid components.Journal of thoracic disease · 2023Article
- PD-L1 Expression is not a Predictive Factor for Recurrence in Resected Non-small Cell Lung Cancer.Lung · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeKnowledge regarding programmed death-ligand 1 (PD-L1) expression in lung cancer is limited. We aim to clarify PD-L1-positive expression in non-small-cell lung cancer (NSCLC), including adenocarcinoma subtypes.
methodsIn all, 90 NSCLC specimens containing various adenocarcinoma subtypes, in addition to squamous cell carcinoma and large-cell carcinoma were selected. PD-L1 was immunohistochemically stained by murine monoclonal antibody clone 22C3.
resultsWhen PD-L1-positive expression was defined by tumor proportion score (TPS) ≥1%, the positive cases were 0/11 in adenocarcinoma in situ, 0/12 in minimally invasive adenocarcinoma, 1/10 in lepidic predominant adenocarcinoma, 1/13 in papillary predominant adenocarcinoma, 8/14 in acinar predominant adenocarcinoma, 6/11 in solid predominant adenocarcinoma, 0/3 in micropapillary predominant adenocarcinoma, 0/4 in invasive mucinous adenocarcinoma, 4/9 in squamous cell carcinoma, and 2/3 in large-cell carcinoma. PD-L1 positivity was higher in males, smokers, advanced pathologic stages, positive vessel invasion, and positive lymphatic invasion. Postoperative survival analysis revealed that PD-L1-positive expression was a significantly worse prognostic factor in univariate analysis for recurrence-free survival (RFS).
conclusionPD-L1-positive tumors were frequent in acinar predominant adenocarcinoma and solid predominant adenocarcinoma than other adenocarcinoma subtypes. PD-L1 expression seemed to increase according to pathologic tumor progression, suggesting a worse postoperative prognosis in NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.